Podcast appearances and mentions of Matthew Harrison

women president australia pr approval ordination lutheran church matt harrison matthew harrison

Play Episode Listen Later Oct 7, 2024 21:43

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Take Courage: Encouraging Words for Discouraging Times The post 2814. The Lutheran Church of Australia's Approval of Women's Ordination – Pr. Matt Harrison, 10/7/24 first appeared on Issues, Etc..

From the Heart of Canada: Crafting Creativity

canada heart creativity crafting winnipeggers matthew harrison

Play Episode Listen Later Aug 22, 2024 38:37

What does it take to chase your dreams?

2183. The Apostle Paul’s Collection for the Jerusalem Church – Pr. Matt Harrison, 8/5/24

president pr apostles collection apostle paul jerusalem church matt harrison matthew harrison

Play Episode Listen Later Aug 5, 2024 34:28

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod The Collection: Mercy in Action LCMS Mercy The post 2183. The Apostle Paul's Collection for the Jerusalem Church – Pr. Matt Harrison, 8/5/24 first appeared on Issues, Etc..

From the Heart of Canada: Winipek with Niigaan Sinclair

canada heart indigenous visions winnipeg manitoba sinclair matthew harrison

Play Episode Listen Later Jul 29, 2024 52:42

Niigaan Sinclair, a columnist, professor, and author, has both studied and lived the Indigenous experience in Manitoba. His book, Wînipêk: Visions of Canada from an Indigenous Centre, explores Winnipeg as the "ground zero" of Indigenous relations in Canada. From the Heart of Canada, Matthew Harrison invites Sinclair to discuss Manitoba's history, Indigenous communities, radical solutions to injustice and violence, and reconciliation.

From the Heart of Canada: Unpacking Trumpism

canada heart unpacking trumpism matthew harrison

Play Episode Listen Later Jul 26, 2024 24:26

In his latest segment of From the Heart of Canada, Matthew Harrison explores the phenomenon of "Trumpism" and the ascent of the controversial president. What attracted his audience? What drove the far-right movement? And what are the implications for Canada? Let's delve into the politics.

Insights with NetSupport - ISTE 2024 edition: Inclusive esports programs in schools with Matthew Harrison and Jess Rowlings

NetSupport Radio

Play Episode Listen Later Jul 15, 2024 9:01

Maggie is joined by Matthew and Jess from the The University of Melbourne to discuss inclusive esports programs in schools.Jess and Matthew are conducing research to understand the gaps in regional and rural areas around resources and infrastructure of and how they can help remove some of those barriers for schools and families, helping students to have equity learning experiences whilst enjoying esports. They have also looked at inclusivity for females in esports, and ways to make it more accessible and better represented.

university schools melbourne programs inclusive esports iste matthew harrison

From the Heart of Canada: Defining Métis Identity

canada identity heart defining indigenous federation matthew harrison

Play Episode Listen Later Jul 12, 2024 50:49

Will Goodon from the Manitoba Métis Federation joins Matthew Harrison at the U Multicultural studio to delve into the history which shaped Métis nationhood. The two explore Indigenous identity fraud and its threat to authentic Métis culture and heritage. Who are the Métis people? What does the future look like for the Métis Nation? Find out from the Heart of Canada.

From the Heart of Canada - Running With Ryan Keeping

canada starting running heart johns halifax newfoundland stroke foundation matthew harrison

Play Episode Listen Later Jul 3, 2024 16:07

How can a person make a difference in the world? Ryan Keeping, a 27-year-old from Halifax, has been running across Canada to find that answer. Starting on April 1st from St. Johns, Newfoundland, Ryan aims to cover 7,386 km in 99 days, running 75 km daily to raise funds for the Heart & Stroke Foundation of Canada. Matthew Harrison ran with Ryan to hear his story.

Sharathon 2024: LCMS President Harrison

The Coffee Hour from KFUO Radio

Play Episode Listen Later Apr 18, 2024 10:04

Why is it important to hear God's Word daily? Rev. Dr. Matthew Harrison, President of The Lutheran Church—Missouri Synod, joins Sarah during Sharathon 2024 to talk about the treasure of God's Word, what he would say to the team of founders of KFUO as they were considering this new medium of AM Radio 100 year ago, and how important our listeners and donors are as we continue this radio ministry for another 100 years. Learn more about Sharathon 2024 and give now at kfuo.org/sharathon.

god president rev am radio lcms lutheran church missouri synod matthew harrison kfuo

247.Inspiration and Inerrancy of the Bible

Casting Nets Podcast

Play Episode Listen Later Nov 16, 2023 54:34

we looked at President Matthew Harrison's (LCMS) article on Divine Authority and a unpublished article by Jack Cascione that was a reaction to it. https://witness.lcms.org/2023/divine-authority/

bible inspiration inerrancy lcms divine authority matthew harrison

Dr. Matthew Harrison: Digital Solutions for Inclusive Leadership

Boiling Point Podcast

Play Episode Listen Later Aug 23, 2023 45:23

In this episode, Emily and Dave sit down with Dr. Matthew Harrison, a seasoned educator and digital innovator. Matt's journey from an accidental teacher to a champion of neurodiversity and inclusion unveils the unexpected ways gaming can foster social skills and empowerment. Matt's passion for utilizing technology to enhance social capacity building, belonging, and inclusion in education comes to the forefront. As a gamer himself, he sheds light on the transformative power of gaming in developing crucial social skills, ranging from turn-taking to effective communication. Through personal anecdotes and insights, he emphasizes how gaming can be a potent tool for leadership development, paving the way for a more inclusive society. The conversation takes a deep dive into the concept of "gaming for good." Matt discusses the innovative initiative, Next Level Collaboration—a program that employs cooperative video games to empower neurodivergent children. With co-founder and Next Level Collaboration CEO, Jess Rowlings, they not only bring lived experience to the table but also a vision for using gaming to boost confidence and social capabilities in young individuals. This venture showcases how unconventional approaches can lead to remarkable outcomes in education and leadership. Beyond gaming, the discussion expands to the significance of accessibility in leadership. Dr. Harrison provides practical insights for leaders and organizations to make workplaces more accessible and inclusive, highlighting the untapped potential of existing accessibility features within common tools and platforms. His emphasis on understanding preferred communication styles and integrating technology underscores the importance of creating environments where everyone can thrive. As the conversation wraps up, Emily and Dave reflect on the episode's key takeaways. Listeners are left with a fresh perspective on leadership—a reminder that fostering inclusion requires embracing diverse tools and strategies. Learn more about your ad choices. Visit megaphone.fm/adchoices

inclusive leadership digital solutions matthew harrison

Rumination Thursday: What is a Lutheran?

Law and Gospel with Pastor Tom Baker

Play Episode Listen Later Aug 3, 2023 27:43

Pastor Baker discusses theological distinctions between Law & Gospel with guest Pastor Wes Reimnitz. Today's rumination topic is what a Lutheran is. Read the article from President Matthew Harrison at reporter.lcms.org/2023/what-is-a-lutheran. Law and Gospel is independently produced by Pastor Tom Baker. Views and opinions expressed on this program may not represent the official position of the management or ownership of KFUO Radio, The Lutheran Church—Missouri Synod. To contact Pastor Tom Baker, email tombaker@brick.net.

law gospel views lutheran rumination lutheran church missouri synod matthew harrison

The Timeline of Recriminations

Stone Choir

Play Episode Listen Later May 31, 2023 226:46

In this episode, we go through the timeline of what has transpired since the LCMS — largely at the behest of Matthew Harrison — published the so-called “Annotated Large Catechism”. The behavior of Synod has been anything but Christian, and wicked deeds should be exposed to the light of day. Satan is on the move, and far too many men in collars are far too willing to do his bidding. Subscribe to the podcast here. Show Notes “The New Large Catechism of the LC-MS stream” “The Apostasy of Missouri” Article includes ‘complaint' letter from Ben Meyer, Daniel Ross, and Erik Johnson, video of interaction with police, and video of Maanum's (first) announcement. “The Book of Concord Will Endure” Lutherans for Racial Justice [archive link] Bios for Matthew Gonzalez and Joshua Salzberg [archive link] “He Believes Hitler Went to Heaven — and Wants to Take Over the Lutheran Church” [archive link] https://twitter.com/CoreyJMahler/status/1616490061377175573?s=20 https://twitter.com/CoreyJMahler/status/1616581582612987906?s=20 See Also 1st Thread from Ryan Turnipseed [Twitter] 2nd Thread from Ryan Turnipseed [Twitter] "Talking Heads: On Headship, Teaching, and Women in the Church” “Against the Antichrist" “Statement on the death of George Floyd and the ensuing riots” [archive link] “Letter to President Harrison of the LCMS” Contrast Harrison's Response to the Terrorist Attack in Waukesha [This is not actually a link because he said nothing about it.] “Waukesha: One Year Later” Further Reading "‘In All Things': 20,000 attend LCMS Youth Gathering” LCMS National Youth Gathering Kennedy v. Louisiana [Wikipedia] Warning: This fact pattern is deeply unpleasant. Lawrence v. Texas [Wikipedia] “Test of Pastoral Orthodoxy” This article is another reason some LCMS pastors are less than fond of me (Mahler). “Of Fools and Demons” A bit more about our adversaries. Parental Warnings This episode will probably not interest children, and some sensitive topics (including pedophilia and rape) are briefly discussed throughout. Errata At one point, I (Mahler) state that I handed the AALC a hard drive with information pertaining to Jordan Cooper, but I misspoke, because what I handed them was, in fact, a flash drive.

Sharathon 2023: President Matthew Harrison

The Coffee Hour from KFUO Radio

Play Episode Listen Later Apr 27, 2023 12:27

Rev. Dr. Matthew Harrison, President of The Lutheran Church—Missouri Synod, joins Andy and Sarah during Sharathon 2023 to talk about how KFUO Radio is a valuable part of the mission and work of The Lutheran Church—Missouri Synod, the importance of hearing and studying God's Word regularly, and the importance of the listener support for this broadcast ministry. It's Sharathon 2023, and we need YOUR support! By God's grace and with your generous support, we've been sharing the Gospel for close to 99 years to millions of listeners worldwide. Our Bible studies help to explain and deepen your understanding of God's Word. Our worship services proclaim salvation in Christ and give you the words that the church has always used to proclaim the Gospel. And our hymns—the sacred music of the church—are the joyous exultation of God's people that explain, proclaim, and announce the joy of salvation in Christ alone. In short, your gift makes it possible for the listener-supported Broadcast Ministry of KFUO Radio to continue filling our world with God's Word. Start, sustain, or strengthen your partnership with KFUO Radio during Sharathon 2023. Give now at kfuo.org/sharathon.

god jesus christ president bible gospel rev by god lutheran church missouri synod matthew harrison

Special Encore: U.S. Pharmaceuticals - The Future of Genetic Medicine

conversations healing trauma resilience talent mozart new science acting teacher matthew harrison

Play Episode Listen Later Mar 23, 2023 8:00

Original Release on February 6th, 2023: As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. ----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Head of U.S. Pharma for Morgan Stanley Research. Matthew Harrison: And I'm Matthew Harrison, Head of U.S. Biotech. Terence Flynn: And on this special episode of Thoughts on the Market, we'll be discussing the bold promise of genetic medicine. It's Monday, February 6th, at 10 a.m. in New York. Terence Flynn: 2023 marks 20 years since the completion of the Human Genome Project. The unprecedented global scientific collaboration that generated the first sequence of the human genome. The pace of research in molecular biology and human genetics has not relented since 2003, and today we're at the start of a real revolution in the practice of medicine. Matthew what exactly is genetic medicine and what's the difference between gene therapy and gene editing? Matthew Harrison: As I think about this, I think it's important to talk about context. And so as we've thought about medical developments and drug development over the last many decades, you started with pills. And then we moved into drugs from living cells. These are more complicated drugs. And now we're moving on to editing actual pieces of our genome to deliver potentially long lasting cures. And so this opens up a huge range of new treatments and new opportunities. And so in general, as we think about it, they're basically two approaches to genetic medicine. The first is called gene therapy, and the second is called gene editing. The major difference here is that in gene therapy you just deliver a snippet of a gene or pre-programmed message to the body that then allows the body to make the protein that's missing, With gene editing, instead what you do is you go in and you directly edit the genes in the person's body, potentially giving a long lasting cure to that person. So obviously two different approaches, but both could be very effective. And so, Terence, as you think about what's happening in research and development right now, you know, how long do you think it's going to be before some of these new therapies make it to market? Terence Flynn: As we think about some of the other technologies you mentioned, Matthew, those took, you know, decades in some cases to really refine them and broaden their applicability to a number of diseases. So we think the same is likely to play out here with genetic medicine, where you're likely to see an iterative approach over time as companies work to optimize different features of these technologies. So as we think about where it's focused right now, it's being primarily on the rare genetic disease side. So diseases such as hemophilia, spinal muscular atrophy and Duchenne muscular dystrophy, which affect a very small percentage of the population, but the risk benefit is very favorable for these new medicines. Now, there are currently five gene therapies approved in the U.S. and several more on the horizon in later stage development. No gene editing therapies have been approved yet, but there is one for sickle cell disease that could actually be approved next year, which would be a pretty big milestone. And the majority of the other gene editing therapies are actually in earlier stages of development. So it's likely going to be several years before those reach the market. As, again as we've seen happen time and time again in biopharma as these new therapies and new platforms are rolled out they have very broad potential. And obviously there's a lot of excitement here around these genetic medicines and thinking about where these could be applied. But I think before we go there, Matthew, obviously there are still some hurdles that needs to be addressed before we see a broader rollout here. So maybe you could touch on that for us. Matthew Harrison: You're right, there are some issues that we're still working through as we think about applying these technologies. The first one is really delivery. You obviously can't just inject some genes into the body and they'll know what to do. So you have to package them somehow. And there are a variety of techniques that are in development, whether using particles of fat to shield them or using inert viruses to send them into the body. But right now, we can't deliver to every tissue in every organ, and so that limits where you can send these medicines and how they can be effective. So there's still a lot of work to be done on delivery. And the second is when you go in and you edit a gene, even if you're very precise about where you want to edit, you might cause some what we call off target effects on the edges of where you've edited. And so there's concern about could those off target effects lead to safety issues. And then the third thing which we've touched on previously is durability. There's potentially a difference between gene therapy and gene editing, where gene editing may lead to a very long lasting cure, where different kinds of gene therapies may have longer term potential, but some may need to be redosed. Terence, as we turn back to thinking about the progress of the pipeline here, you know, what are the key catalysts you're watching over 23 and 24? Terence Flynn: You know, as everyone probably knows, biopharma is a highly regulated industry. We have the FDA, the Food and Drug Administration here in the U.S., and we have the EMA in Europe. Those are the bodies that, you know, evaluate risk benefit of every therapy that's entering clinical trials and ultimately will reach the market. So this year we're expecting much of the focus for the gene editing companies to be broadly on regulatory progress. So again, this includes completion of regulatory filings here in the U.S. and Europe for the sickle cell disease drug that I mentioned before. And then something that's known as an IND filing. So essentially what companies are required to do is file that before they conduct clinical trials in humans in the U.S. There are companies that are pursuing this for hereditary angioedema and TTR amyloidosis. Those, if successful, would allow clinical trials to be conducted here in the U.S. and include U.S. patients. The other big thing we're watching is additional clinical data related to durability of efficacy. So, I think we've seen already with some of the gene therapies for hemophilia that we have durable efficacy out to five years, which is very exciting and promising. But the question is, will that last even longer? And how to think about gene therapy relative to gene editing on the durability side. And then lastly, I'd say safety. Obviously that's important for any therapy, but given some of the hurdles still that you mentioned, Matthew, that's obviously an important focus here as we look out over the longer term and something that the companies and the regulators are going to be following pretty closely. So again, as we think about the development of the field, one of the other key questions is access to patients. And so pricing reimbursement plays a key role here for any new therapy. There are some differences here, obviously, because we're talking about cures versus traditional chronic therapies. So maybe Matthew you could elaborate on that topic. Matthew Harrison: So as you think about these genetic medicines, the ones that we've seen approved have pretty broad price ranges, anywhere from a million to a few million dollars per patient, but you're talking about a potential cure here. And as I think about many of the chronic therapies, especially the more sophisticated ones that patients take, they can cost anywhere between tens of thousands and hundreds of thousands of dollars a year. So you can see over a decade or more of use how they can actually eclipse what seems like a very high upfront price of these genetic medicines. Now, one of the issues obviously, is that the way the payers are set up is different in different parts of the world. So in Europe, for example, there are single payer systems for the patient never switches between health insurance carriers. And so therefore you can capture that value very easily. In the U.S., obviously it's a much more complicated system, many people move between payers as they switch jobs, as you change from, you know, commercial payers when you're younger to a government payer as you move into Medicare. And so there needs to be a mechanism worked out on how to spread that value out. And so I think that's one of the things that will need to evolve. But, you know, it's a very exciting time here in genetic medicine. There's significant opportunity and I think we're on the cusp of really seeing a robust expansion of this field and leading to many potential therapies in the years to come. Terence Flynn: That's great, Matthew. Thanks so much for taking the time to talk today. Matthew Harrison: Great speaking with you, Terrence. Terence Flynn: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on Apple Podcasts app. It helps more people to find the show.

Acting Teacher Matthew Harrison - Why You Don't Have Talent

10-1

Play Episode Listen Later Mar 16, 2023 75:01

We all know individuals who are good at a skill without even trying. They can write, play a sport, or play an instrument with seemingly no effort. Is it possible that some people are just more talented than others? If so, does that apply to acting as well? Today, acting Coach Matthew Harrison and I delve deep into the concept of talent; where the idea came from and why society is obsessed by it. We discuss why Mozart had no talent and how some actors can give incredible performances without any prior training. Our conversation references some of the celebrated neuroscientists and psychologist listed below: Anders Ericsson - PEAK: Secrets from the New Science of Expertise David Eagleman - LIVEWIRED -The inside story of the ever changing brain David Eagleman - THE RUNAWAY SPECIES- How human creativity remakes the world Brene Brown - DARING GREATLY Other books of interest: Yuval Noah Harari - HOMO SAPIENS Gabor Maté - IN THE REALM OF HUNGRY GHOSTS Gabor Maté - WHEN THE BODY SAYS NO Daniel Kanneman - THINKING FAST AND SLOW Brene Brown - THE POWER OF VULNERABILITY Oprah Winfrey - WHAT HAPPENED TO YOU?: Conversations on Trauma, Resilience, and Healing

Against the Antichrist

Stone Choir

Play Episode Listen Later Mar 15, 2023 152:09

Matthew Harrison is head of the largest (supposedly) Confessional Lutheran body in the Western world — the LCMS. During his tenure, he has overseen the greatest decline in membership in the history of the LCMS, the closure of LCMS schools and congregations, and the collapse of LCMS organizations. Now, to top off his legacy, Harrison is pushing false doctrine via 'new' versions of core confessional, Lutheran documents (e.g., the Small Catechism and the Large Catechism). He is even exporting this doctrine abroad. Of course, the focus on exporting doctrine is nothing new — Harrison has spent his tenure with his focus everywhere but on the sheep God entrusted to his care (and for which God will one day command him to account). Harrison and those around him personally hate this podcast and its hosts, because we are speaking the truth about the Christian faith and about what men like Harrison are doing to the Church. In this episode, we review Harrison's recent letter 'denouncing disturbing ideologies'. Christians do not speak as Harrison speaks. We will all have to choose a side. For their part, the following men have thrown in their lot with Satan and the kingdom of Antichrist: Matthew Harrison, President of the LCMS Peter K. Lange, 1st Vice President of the LCMS John C. Wohlrabe Jr., 2nd Vice President of the LCMS Scott R. Murray, 3rd Vice President of the LCMS Nabil S. Nour, 4th Vice President of the LCMS Christopher Esget, 5th Vice President of the LCMS Benjamin T. Ball, 6th Vice President of the LCMS the 35 District Presidents of the LCMS Subscribe to the podcast here. Show Notes "President Harrison denounces disturbing ideologies" "Statement on the death of George Floyd and the ensuing riots" The New Catechism of the LC-MS [YouTube] YouTube review of the 'Annotated' LC. See Also Coverture [Wikipedia] "The Stranger" by Rudyard Kipling "Letter to President Harrison of the LCMS" "Test of Pastoral Orthodoxy" "We Are Stronger Together" "The Apostasy of Missouri" Further Reading C. F. W. Walther on Slavery, Humanism, and the Bible Antifaschistische Aktion "On the Year-Zero Revolutionary" Parental Warnings The word "jackass" is used once in this episode at around 01:30:00.

The Apostasy of Mammonburg (2/27/2023)

Mammonburg

Play Episode Listen Later Feb 28, 2023 119:36

In today's episode, your tour guides tell you a story about the Lutheran Church-Missouri Synod and a simple fascist often called "The Slavery Lutheran."Machaira Action exposéThe Apostasy of MissouriFollow us on Twitter @MammonburgpodFollow the hosts on Twitter: Jackal, Finch, Josiah, and Phil.Audio CreditsBaba O'Riley - The WhoDreams - DJ QuadsHungry - LiadiiiSentimental – Dan Darmawan Noah - Calin Moraru BeatsPastor Ben Squires on Recent Events in LCMSMaanum, AnnouncementCorey Mahler arguing with cops lolSimpsons: Lisa creates LutheransDisco Elysium: EggheadTrump about CharlottesvilleJason Kessler after CharlottesvilleJordan B Cooper on Christian NationalismNBC: Christian Nationalism On The RiseVacation Sex

The Flyover View, February 10, 2023 | Heartland Politics, News, and Views

Heartland POD

Play Episode Listen Later Feb 10, 2023 14:49

Host: Kevin Smith Dives into the weekly news most impactful to the HeartlandHEADLINESA Mighty Controversy Is This Lutheran Catechism - Christianity Today - https://www.christianitytoday.com/news/2023/february/lutheran-catechism-concordia-publishing-critics-matthew-har.html?fbclid=IwAR1fTmGTD5bmljUm-3HBHoRFC5hLjOje6grzS6mBva7gNUEWM8nxhYvfRew_aem_Abw0xp27VoagVA-hQ7b1jmV9_JapK22txw534SD7aQXJ5G56w_NVpU5qBLinbl0HeGWP843SZL01HxQ3AwkN4A10p-nKzngDDxaiJHUkHX8dKbbAeztj2L-ofhC-x1Xbe4DkeYmYvQD04fuyzi_UwtrQLutherans for Racial Justice - https://lutheransforracialjustice.com/glass-onion?fbclid=IwAR1Qb-1XAlAgwMdvvvuhp33CjmmO1MVlioPa0fxhXczOFH1NlEPjPISwqZELIGHTNING ROUNDMontanaBill in the state Legislature seeks to regulate science curriculum in public schools.Montana Public Radio - https://www.mtpr.org/montana-news/2023-02-07/bill-would-ban-the-teaching-of-scientific-theories-in-montana-schools?utm_medium=social&utm_source=facebook.com&utm_term=nprnews&utm_campaign=npr&fbclid=IwAR392qd4WeNdpxNhtV73I8wVEXKXOOubKD9qdqzMGInE6P0KVobnrUkkZWw&mibextid=Zxz2cZArizonaFraud rampant in school-voucher program!AZ Central - https://www.azcentral.com/story/news/politics/arizona/2018/10/29/misspent-school-voucher-funds-exceed-700-k-little-recovered/1780495002/?fbclid=IwAR3Hu6hobnEXTu2ayvOSaGA7Xdf8um1VVirHq_OO8vnW0RMtbt22EKAErwk&mibextid=Zxz2cZ#ldw15g70l8d7ldvqauhSuper Bowl LVII betting.Wall Street Journal - https://www.wsj.com/articles/super-bowl-betting-projected-to-hit-record-16-billion-11675731607KansasOld homeowners get grantsShawnee Mission Post - https://shawneemissionpost.com/2023/02/07/lenexa-home-improvement-grants-193186/New homeowners get helpYahoo Finance - https://finance.yahoo.com/news/kansas-first-time-homebuyer-assistance-161649713.htmlMissouriOSHA fines against a Lone Jack, Missouri, cattle processor. KSHB Kansas - https://www.kshb.com/news/local-news/lone-jack-cattle-processor-again-facing-osha-fines-over-workplace-safety-concerns#MOLeg Republicans an emphatic YES! for kids parading with guns.The Guardian - https://www.theguardian.com/us-news/2023/feb/09/missouri-rejects-ban-children-carrying-guns-in-publicThe first weekend numbers are in after legalized marijuana hit the state of Missouri.Leafly - https://www.leafly.com/news/politics/missouri-tops-12-million-in-marijuana-sales-during-opening-rec-weekendOklahomaTranquil Trans Protest.Fox News - https://okcfox.com/news/local/protests-at-state-capitol-sparking-nationwide-outrage-gov-governor-kevin-stitt-ok-oklahoma-state-of-the-state-transgender-trans-gender-rights-pro-law-legislature-legislative-gender-affirming-care-trust-women-freedom-oklahomaIowaThe U.S. Department of Labor vs Construction Bad Actors.Iowa Capital Dispatch - https://iowacapitaldispatch.com/2023/02/03/feds-file-lawsuits-accusing-two-iowa-companies-of-labor-violations/Medical malpractitioners protected by state republicansDes Moines Register - https://www.desmoinesregister.com/story/news/politics/2023/02/08/iowa-house-votes-to-limit-medical-malpractice-damages-a-gop-priority/69866480007/Lastly, The Trifurcation of the GOPIndy 100 - https://www.indy100.com/politics/donald-trump-ron-desantis-republican-party?utm_campaign=Main&utm_content=Echobox&utm_medium=Social&utm_source=Twitter&utm_term=Autofeed#Echobox=1675808611The Guardian - https://www.theguardian.com/us-news/2023/feb/09/nikki-haley-presidential-run-ron-desantis-donald-trump-poll?CMP=Share_iOSApp_Other

The Flyover View, February 10, 2023 | Heartland Politics, News, and Views

The Heartland POD

Play Episode Listen Later Feb 10, 2023 14:49

U.S. Pharmaceuticals: The Future of Genetic Medicine

new york head europe food market fda medicare pharma ind biotech drug administration terence pharmaceuticals human genome project duchenne ttr genetic medicine matthew harrison

Play Episode Listen Later Feb 6, 2023 7:52

As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. ----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Head of U.S. Pharma for Morgan Stanley Research. Matthew Harrison: And I'm Matthew Harrison, Head of U.S. Biotech. Terence Flynn: And on this special episode of Thoughts on the Market, we'll be discussing the bold promise of genetic medicine. It's Monday, February 6th, at 10 a.m. in New York. Terence Flynn: 2023 marks 20 years since the completion of the Human Genome Project. The unprecedented global scientific collaboration that generated the first sequence of the human genome. The pace of research in molecular biology and human genetics has not relented since 2003, and today we're at the start of a real revolution in the practice of medicine. Matthew what exactly is genetic medicine and what's the difference between gene therapy and gene editing? Matthew Harrison: As I think about this, I think it's important to talk about context. And so as we've thought about medical developments and drug development over the last many decades, you started with pills. And then we moved into drugs from living cells. These are more complicated drugs. And now we're moving on to editing actual pieces of our genome to deliver potentially long lasting cures. And so this opens up a huge range of new treatments and new opportunities. And so in general, as we think about it, they're basically two approaches to genetic medicine. The first is called gene therapy, and the second is called gene editing. The major difference here is that in gene therapy you just deliver a snippet of a gene or pre-programmed message to the body that then allows the body to make the protein that's missing, With gene editing, instead what you do is you go in and you directly edit the genes in the person's body, potentially giving a long lasting cure to that person. So obviously two different approaches, but both could be very effective. And so, Terence, as you think about what's happening in research and development right now, you know, how long do you think it's going to be before some of these new therapies make it to market? Terence Flynn: As we think about some of the other technologies you mentioned, Matthew, those took, you know, decades in some cases to really refine them and broaden their applicability to a number of diseases. So we think the same is likely to play out here with genetic medicine, where you're likely to see an iterative approach over time as companies work to optimize different features of these technologies. So as we think about where it's focused right now, it's being primarily on the rare genetic disease side. So diseases such as hemophilia, spinal muscular atrophy and Duchenne muscular dystrophy, which affect a very small percentage of the population, but the risk benefit is very favorable for these new medicines. Now, there are currently five gene therapies approved in the U.S. and several more on the horizon in later stage development. No gene editing therapies have been approved yet, but there is one for sickle cell disease that could actually be approved next year, which would be a pretty big milestone. And the majority of the other gene editing therapies are actually in earlier stages of development. So it's likely going to be several years before those reach the market. As, again as we've seen happen time and time again in biopharma as these new therapies and new platforms are rolled out they have very broad potential. And obviously there's a lot of excitement here around these genetic medicines and thinking about where these could be applied. But I think before we go there, Matthew, obviously there are still some hurdles that needs to be addressed before we see a broader rollout here. So maybe you could touch on that for us. Matthew Harrison: You're right, there are some issues that we're still working through as we think about applying these technologies. The first one is really delivery. You obviously can't just inject some genes into the body and they'll know what to do. So you have to package them somehow. And there are a variety of techniques that are in development, whether using particles of fat to shield them or using inert viruses to send them into the body. But right now, we can't deliver to every tissue in every organ, and so that limits where you can send these medicines and how they can be effective. So there's still a lot of work to be done on delivery. And the second is when you go in and you edit a gene, even if you're very precise about where you want to edit, you might cause some what we call off target effects on the edges of where you've edited. And so there's concern about could those off target effects lead to safety issues. And then the third thing which we've touched on previously is durability. There's potentially a difference between gene therapy and gene editing, where gene editing may lead to a very long lasting cure, where different kinds of gene therapies may have longer term potential, but some may need to be redosed. Terence, as we turn back to thinking about the progress of the pipeline here, you know, what are the key catalysts you're watching over 23 and 24? Terence Flynn: You know, as everyone probably knows, biopharma is a highly regulated industry. We have the FDA, the Food and Drug Administration here in the U.S., and we have the EMA in Europe. Those are the bodies that, you know, evaluate risk benefit of every therapy that's entering clinical trials and ultimately will reach the market. So this year we're expecting much of the focus for the gene editing companies to be broadly on regulatory progress. So again, this includes completion of regulatory filings here in the U.S. and Europe for the sickle cell disease drug that I mentioned before. And then something that's known as an IND filing. So essentially what companies are required to do is file that before they conduct clinical trials in humans in the U.S. There are companies that are pursuing this for hereditary angioedema and TTR amyloidosis. Those, if successful, would allow clinical trials to be conducted here in the U.S. and include U.S. patients. The other big thing we're watching is additional clinical data related to durability of efficacy. So, I think we've seen already with some of the gene therapies for hemophilia that we have durable efficacy out to five years, which is very exciting and promising. But the question is, will that last even longer? And how to think about gene therapy relative to gene editing on the durability side. And then lastly, I'd say safety. Obviously that's important for any therapy, but given some of the hurdles still that you mentioned, Matthew, that's obviously an important focus here as we look out over the longer term and something that the companies and the regulators are going to be following pretty closely. So again, as we think about the development of the field, one of the other key questions is access to patients. And so pricing reimbursement plays a key role here for any new therapy. There are some differences here, obviously, because we're talking about cures versus traditional chronic therapies. So maybe Matthew you could elaborate on that topic. Matthew Harrison: So as you think about these genetic medicines, the ones that we've seen approved have pretty broad price ranges, anywhere from a million to a few million dollars per patient, but you're talking about a potential cure here. And as I think about many of the chronic therapies, especially the more sophisticated ones that patients take, they can cost anywhere between tens of thousands and hundreds of thousands of dollars a year. So you can see over a decade or more of use how they can actually eclipse what seems like a very high upfront price of these genetic medicines. Now, one of the issues obviously, is that the way the payers are set up is different in different parts of the world. So in Europe, for example, there are single payer systems for the patient never switches between health insurance carriers. And so therefore you can capture that value very easily. In the U.S., obviously it's a much more complicated system, many people move between payers as they switch jobs, as you change from, you know, commercial payers when you're younger to a government payer as you move into Medicare. And so there needs to be a mechanism worked out on how to spread that value out. And so I think that's one of the things that will need to evolve. But, you know, it's a very exciting time here in genetic medicine. There's significant opportunity and I think we're on the cusp of really seeing a robust expansion of this field and leading to many potential therapies in the years to come. Terence Flynn: That's great, Matthew. Thanks so much for taking the time to talk today. Matthew Harrison: Great speaking with you, Terrence. Terence Flynn: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on Apple Podcasts app. It helps more people to find the show.

3352. Decision Theology – Pr. Matt Harrison, 12/1/22

president pr decision theology matt harrison matthew harrison

Play Episode Listen Later Dec 1, 2022 40:14

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?

378 - Matthew Harrison on Managing MSK Conditions.

Modern Mindset with Adam Cox

Play Episode Listen Later Oct 11, 2022 10:07

Adam Cox is joined by Matthew Harrison, First Contact Physiotherapy Clinical Project Manager, to discuss what MSK conditions are and how the current climate can impact MSK health. He explains how people can stay active during the winter, and what the Chartered Society of Physiotherapy is. https://www.csp.org.uk/

managing conditions physiotherapy msk adam cox matthew harrison chartered society

2491. The Past, Present & Future of Confessional Lutheranism – Pr. Matt Harrison, 9/6/22

president pr past present confessional lutheranism matt harrison matthew harrison

Play Episode Listen Later Sep 6, 2022 28:59

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?

2071. The Incarnation and Scripture – Pr. Matt Harrison, 7/26/22

president pr scripture incarnation matt harrison matthew harrison

Play Episode Listen Later Jul 26, 2022 30:53

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?

Episode 27 - Paul Matthew Harrison

Hello from the Bus

Play Episode Listen Later Jul 13, 2022 133:21

Author Paul Matthew Harrison, best known for his 2 volume portraiture of the friendship between he and mewithoutyou front-man, Aaron Weiss, joins to chat.

mental health psychology spirituality jung mewithoutyou matthew harrison aaron weiss

220703 Sermon on the overturning of Roe vs. Wade

Rev. Michael Holmen's Sermons

Play Episode Listen Later Jul 3, 2022

Audio recordingSermon manuscript:Our goal as Christians is to inherit heaven. Since this is our goal, we should be heavenly minded people. We should not seek to please ourselves or our fellow human beings. If we or others are pleased, then that is all well and good, but it is not what we are to be after. We seek to be pleasing to God. What is pleasing to him is his commandments. God's commandments are good, and they are always for the good. However, it does not always seem that God's commandments are for the good. Take, for example, “Honor your father and your mother.” We don't always agree with our parents and other authorities. Honoring father and mother often means that we can't do what we want to do. Or, on the other hand, we have to do what we don't want to do. That's no fun. So even though God's commandments are for our good, they often don't seem that way to us. That disconnect is maybe the primary reason why we don't do what God's commands us to do. Since our flesh often doesn't see the value of God's commandments, and since every human being has this sinful flesh, it isn't surprising that the same kind of thing that happens with us as individuals also ends up happening with groups of people, such as with states or with nations. Let's consider our own nation. God commands us not to steal. Folks know this because he has written this truth on everyone's heart. But there is no end to the swindling, corruption, fraud, and so on that happens on a daily basis. This has gotten quite sophisticated, in fact. The worst criminals among us are not the petty thieves or embezzlers that make it into the papers. They end up getting 10 year prison sentences. The worst thieves are the ones that never get prosecuted. The real big shots, throwing around billions, take whatever they can get while accomplishing nothing productive or helpful to others. They are basically a bunch of gamblers. When they win with their rigged bets in stocks and trades they are happy to take the profits. When they lose they get the government to bail them out. These thieves do not go to jail. They are highly exalted. They are hailed as great philanthropists. After their life of crime, screwing over whomever they possibly could, they hand out a small portion of their ill-gotten gains as charity. They get buildings named after them. To summon a nation to take up such fraud and corruption is a huge ask. Only the most youthful and vigorous of nations—nations that still have a sense for right and wrong—will dare to do it. Fighting wealthy and powerful people who can bribe and appoint and finagle, with the best lawyers helping them all along the way—that is dangerous and thankless. It is much easier to let things slide. So that's what we've done. That is what we will continue to do. We'll let things continue to decompose. That's how it is with so many other matters of right and wrong too. When it comes to marriage and family our nation has almost completely checked out of its responsibility to regulate that area of life. Judges used to be involved in keeping marriages together. There used to be no such thing as a no-fault divorce. People were not allowed to publicly present themselves as sexual partners with whomever they wanted. But, you know what? That's a lot of work! Getting involved in such matters is messy. It's dangerous and thankless. For several generations now parents, as God-given authorities, have also not wanted to touch the issue of their children fornicating or living together with someone to whom they are not married. God's commandment, “You shall not commit adultery,” is for our good, but it often does not seem that way. It often seems much more sensible to say, “Live, and let live.” There's no question that “Live, and let live,” is vastly easier. This laziness and apathy are also what is most important when it comes to the fifth commandment: “You shall not murder.” It seems much easier to terminate the life of an unwanted, unborn child than to be saddled with the burden of raising such a child. Unborn children who suffer from diseases are especially prone to being unwanted, and therefore murdered. A horrifying statistic that I learned when Edith was still in the womb is that 90% or more of the children who are identified as possibly to having Downs Syndrome are aborted. Caring for a child who has that condition is certainly daunting, but that is no excuse for strangling them or poisoning them. The same thing is true also at the other end of life. Several states in our nation already have laws legalizing physician-assisted suicide. Physician assisted suicide is when physicians prescribe poison to people who no longer want to live. When a disease is terminal it can seem easiest for everyone involved to just “get it over with” when it comes to a person dying. Why should family or friends waste their time keeping vigil at the death bed when they could be making money? The commandment stands: “You shall not murder.” But it doesn't seem like it is for our good. Ending lives quickly, easily, painlessly, and privately seems to be better for everyone involved. This nation has grown old and tired. The nation, of course, hasn't grown tired of making money, but that is how it is with people, too, in their old age. Greed is a vice that afflicts the elderly. We as a nation are zealous for money, but care very little about what is right and wrong. This makes us very utilitarian about moral issues. If it doesn't appear as though some activity is harmful to others, then, by all means, indulge. Anybody who would dare to make judgments about such things is unhelpful, because we all know that what is really important is the economy. So long as we continue to be the richest, most powerful, first-in-the-world nation, then we must have our priorities straight. This, however, is a very earth-bound judgment, purposely neglecting the one who is in heaven. God does not care if a person lives in America or if a person lives in Haiti. Neither being an American nor a Haitian matters. What matters is being a new creation, created by the Holy Spirit. Greatness is not defined by the amount of money or influence a person has. Greatness is a matter of keeping God's commandments. We should love the Lord our God with all our heart, soul, strength, and mind, and our neighbor as ourselves. To make America great again we do not need this politician or that politician, but a deep change of heart. We need to learn, perhaps for the first time, what true greatness is. True greatness is not democracy or earthly peace. True greatness is following after our Lord Jesus Christ. We are to deny ourselves, study God's commandments and keep them, and bear the cross that will inevitably come as a result of keeping God's commands. There's no way of accomplishing this with some political movement. There's no way to compel anyone to live as a Christian. This is only dealing with individuals. We all, as individuals, must repent of our cold, lazy, apathy towards God's commandments—the cold, lazy apathy that I hope you have seen in yourself even with the few commandments that have been pointed out today. We as individuals are guilty in such matters. We must leave behind our old, selfish attitudes and seek anew the kingdom of God and his righteousness. Let's finally get to the topic I promised you I'd speak about today: Since we have such deeply entrenched spiritual problems in our country, I can't get overly excited about the overturning of Roe vs. Wade. Overturning Roe vs. Wade was a very good thing. Roe vs. Wade was wrong. There is no such thing as a constitutional right to end another person's life. Now states are allowed to decide for themselves whether abortion is legal and under what circumstances. That might save some babies' lives. That's good. But this ruling hasn't done much to change the overall downhill direction our country has been going, spiritually speaking. I've included in your bulletin a letter from our Synod's president, Matthew Harrison. It seems to me that he struck the right tone that we should have as Christians regarding this ruling. He says we should rejoice that something which has done so much to bolster the unjust killing of innocent people has been torn down. He says we should also not be intimidated by those who gnash their teeth and will be working hard to make the murdering of the unwanted easier. Some people will never be convinced that God alone has the right to determine who lives and who dies, and that we should not take that into our own hands. Finally, president Harrison's letter tells us that we should repent. In a way, very little has changed with the overturning of Roe vs. Wade. Our lovelessness and spiritual bankruptcy has not been altered. Our failure to care for troubled and helpless women is just as egregious as it ever was. He ended his letter with: “Lord, have mercy.” This is the way it is with Christianity. We must stay the course that we have been given as Christians. We fight against evil, not just by looking for evil people over there, but by seeing that same evil within ourselves. We repent, believe the Gospel of forgiveness for Jesus's sake, and, God willing, walk by the Spirit. The source of true blessing and happiness has been the same ever since the beginning of creation. That source has always been the Lord our God. He is the one from whom all blessings flow. Adam and Eve were harmed by breaking his commandments, just as anyone and everyone inevitably and always will be harmed by breaking his commandments, even if it doesn't seem so. Adam and Eve were saved through faith in the Lord's promise of a Savior, our Lord Jesus Christ. As it was then, so it is now, and so it ever shall be for each one of us individually, as well as collectively as a state or a nation. A nation, however, cannot repent. Only individuals can repent and believe. If you really want to be helpful and patriotic on this holiday weekend, you would do better to examine your life according to the Ten Commandments than to read the Declaration of Independence. The Declaration of Independence was written by mere men. The commands and promises by which we live as Christians were given to us by God. God's Word is a sure and certain path for us Christians. It is impossible for us not to be blessed if we follow God's commandments and believe his promises. God is God. He will bring it about. No such promise can be made concerning politics or even our fine American system of government. No human measures can ever get deep enough to strangle the evil at its source. God's working is quite different. He makes a new creation. You, as Christians, are new creations. You have been raised with Christ. You are the salt of the earth. See to it that you don't lose your saltiness. Continue on loving and forgiving your family and your friends. Continue with your work, not working for money or for praise, but for the good of those whom God puts into your life. As a summary we might close with these words from Paul: “Set your mind on things above, not on earthly things. For you died, and your life is now hidden with Christ in God. When Christ, who is your life, appears, then you also will appear with him in glory.”

We Got Some Explaining To Do (Mail Bag)

Protect Your Noggin

Play Episode Listen Later Jun 5, 2022 111:53 Very Popular

Jeff and Stacie respond to listener emails and voice messages, largely unpacking our perspectives on the Bible, inerrancy, LGBT inclusion, and traditional social values within conservative Christianity. We also weigh in on the leaked letter from LCMS president Matthew Harrison to the board of regents at Concordia University Wisconsin. If you have known us in our old lives within the orbit of American evangelicalism and conservative Lutheranism, this may infuriate you, but we mean only to share with you honestly what we're thinking and experiencing these days. Stick through hour and ten minutes of banter to hear a discussion of whether sex-positive BDSM dungeons are safer than Christian summer camp.

american bible christianity mail lgbt explaining bdsm lutheranism lcms concordia university wisconsin matthew harrison

1401. Joyfully Lutheran – Pr. Matt Harrison, 5/20/22

president pr lutheran joyfully matt harrison matthew harrison

Play Episode Listen Later May 20, 2022 57:52

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?

Sharathon 2022: President Matthew Harrison

The Coffee Hour from KFUO Radio

Play Episode Listen Later Apr 21, 2022 14:09

The Rev. Dr. Matthew C. Harrison, President of The Lutheran Church—Missouri Synod, joins Andy and Sarah during Sharathon 2022 to talk about why it's important to hear God's Word daily, how KFUO Radio supports listeners in their vocations, and the role of joyful giving in the work of LCMS ministries such as KFUO Radio. Give now for Sharathon 2022 at kfuo.org/sharathon.

god president rev lcms lutheran church missouri synod matthew harrison matthew c harrison

1013. Reflections on the 175th Anniversary of the Lutheran Church Missouri Synod – Pr. Matt Harrison, 4/11/22

president pr reflections lutheran church missouri synod matt harrison matthew harrison

Play Episode Listen Later Apr 11, 2022 26:32

Pr. Matthew Harrison, President of the Lutheran Church-Missouri Synod Why Am I Joyfully Lutheran?

3/4/2022 - Matthew Harrison on the situation in Ukraine with Nik Sandman

KNNA Theological Programming

Play Episode Listen Later Mar 8, 2022 11:22

Nik Sandman interviews Matthew Harrison, President of The Lutheran Church- Missouri Synod, regarding the war between Russia and Ukraine. March 4th, 2022 --- Send in a voice message: https://anchor.fm/knna-broadcasting/message

president russia ukraine situation sandman lutheran church missouri synod matthew harrison

Who needs to repent?

David Bahn - Reflections

Play Episode Listen Later Jan 24, 2022 6:06

We have all manner of leaders and powerful people who care more about their power than their relationship with God. But even if they don't repent we must. And that is the second truth: now is the time for us to repent. Joe Biden is President of the United States. Vladimir Putin is President of Russia. Greg Abbot is governor of Texas. Matthew Harrison is President of the LCMS. Michael Newman is President of the LCMS Texas District. You might have thoughts about each of these men and their need to repent. But that is for them to deal with. We each must repent and rejoice in knowing that God has prepared a level and straight path to life and salvation: the path of faith that leads us to Jesus.

united states god jesus christ texas president russia joe biden vladimir putin repent greg abbott lcms michael newman matthew harrison

Andrew Sheets: Challenges to the 2022 Story Emerge

covid-19 europe japan challenges market economic fed omicron federal reserve sheets morgan stanley emerge us federal reserve matthew harrison

Play Episode Listen Later Dec 17, 2021 3:21

With recent signals from the Federal Reserve and new data on the Omicron variant, there's a lot that could impact the shape of 2022, but for now the core of our outlook remains unchanged.----- Transcript -----Welcome to Thoughts on the Market. I'm Andrew Sheets, Chief Cross Asset Strategist for Morgan Stanley. Along with my colleagues, bring you a variety of perspectives, I'll be talking about trends across the global investment landscape and how we put those ideas together. It's Friday, December 17th, at 2 p.m. in London.Every year, the economists and strategists at Morgan Stanley come together and try to forecast what the next year could look like. And then, as always seems to be the case, something happens. The world, after all, is an unpredictable place.This year, these 'somethings' have come thick and fast. As my colleague Matthew Harrison, U.S. biotechnology analyst, and I discussed on this program last week, the Omicron variant appears to be highly contagious and likely to lead to a large wave of winter infections.At almost the same time, the US Federal Reserve, arguably the world's most important central bank, has been sounding less tolerant of inflation, leading Morgan Stanley's economists to now expect a quicker end to the central bank's bond purchases and also a larger, faster increase in Federal Reserve interest rates relative to what we thought just a month ago.Both are major developments. But while they change some of our investment strategy around the edges, we don't think, for now, they change the main story for 2022.To understand why, let's start with the Federal Reserve. Yes, the Fed is now likely to end bond purchases and raise interest rates sooner than we had previously assumed. But from an investment perspective, we always thought the central bank would signal an intent to be less supportive to start the new year, hoping to convince markets that they were taking inflation seriously. We had previously thought that this 'tough talk' might shift in the spring, when inflation data would come down, and the Fed wouldn't ultimately follow through on interest rate hikes. But now, it looks like they will.But in either scenario, the strategy for investors should be to position for a central bank that is indicating it wants to be less supportive. As such, we expect interest rates to move higher, especially around five-year maturities, the dollar to appreciate and U.S. and emerging markets stocks to underperform those in Europe and Japan, where the central banks are going to be more accommodating for longer. We think financials outperform as an equity sector, seeing them as a beneficiary of less central bank accommodation.The other development, of course, is Omicron, while the new variant appears to be highly contagious. Our economists at Morgan Stanley had always assumed some form of a 'winter wave' of COVID in their growth numbers, given the virus's seasonal characteristics. Economic data, for the moment, has actually held up quite well and global activity has been less impacted by each incremental COVID wave. And we also need to consider the entire year, not just what could be a very difficult month or two of high COVID cases. All of these together are why our base case remains for strong global growth in the next year, despite the currently worrying headlines.Both new developments, however, require close observation. The Fed looks much more willing to shift in either direction than it has before, while the full impact of Omicron may not be seen for several more weeks. For now, however, we think a backdrop of good global growth and less central bank support remains the outlook for 2022.Thanks for listening. Subscribe to Thoughts on the Market on Apple Podcasts, or wherever you listen, and leave us a review. We'd love to hear from you.

Matthew Harrison: COVID-19 - Omicron Updates

Play Episode Listen Later Dec 16, 2021 3:31

The last week brought new evidence regarding the transmissibility, immune evasion and disease severity of Omicron, and with it, more clarity on the coming weeks and months.----- Transcript -----Welcome to Thoughts on the Market. I'm Matthew Harrison, Biotechnology Analyst. Along with my colleagues, bringing you a variety of perspectives, today I'll be discussing our updated thoughts on the COVID 19 pandemic and the impact of Omicron. It's Thursday, December 16th at 10:00 a.m. in New York. Since Omicron was first discovered, we've been using the framework of transmissibility, immune evasion and disease severity to think about its impact. Over the last week, the level of evidence on all three topics has increased significantly. So first, on transmissibility. The ability of Omicron to outcompete the prior dominant variant, Delta, now appears clear. We have evidence in South Africa, the UK and Denmark, with Omicron now dominant in central London and set to be the dominant variant in the UK over the next few days. The US is a few weeks behind Europe in terms of spread, but we would expect a similar pattern. Cases are now rising globally, driven by Omicron's transmissibility. This is a combination of factors driven by one, its innate transmissibility, and second, its immune evasion properties, which have dramatically increased the percentage of the population susceptible to infection. We now have multiple studies, which generally come to a similar conclusion. Two doses of vaccination or a single prior infection provide little to no barrier against infection. Two doses of vaccination do, however, provide protection against severe outcomes like hospitalization or death. This is around a 70% relative reduction versus those who are not vaccinated based on preliminary data. Three doses of vaccination or two doses of vaccination and a prior infection provide a greater barrier against infection. Preliminary data here suggests a 75% relative reduction to those without three doses or two doses and a prior infection. Importantly, since a limited proportion of the population has been boosted - we estimate at about mid-teens percentage of the total US population - the vast majority of the population is again susceptible to an infection with Omicron. And finally, on disease severity. The data out of South Africa continue to suggest the percentage of patients with severe outcomes is lower relative to the prior Delta wave. This means that there are less people in the ICU and less people on a ventilator as a proportion of the total people infected compared with Delta. That said, it's important to remember that even with a lower proportion of people having severe disease, if Omicron drives a wave of infections that is much higher than Delta, the overall disease burden could still be very high. So this leads us to what is our outlook on infections and the ultimate impact of Omicron. The variant is likely to be dominant quickly, and we would expect to be in the steeper part of the exponential rise in cases here in the US in the next two to three weeks. We believe it is possible that the Omicron wave could have a peak in terms of total number of infections that is somewhere between 2 and 3 times higher than the prior Delta wave. However importantly, vaccination should help protect against severe outcomes. For more on Omicron, we also recently sat down for an interview with the Moderna CEO Stephane Bancel to discuss his views on that topic and more. You can see the full interview on MorganStanley.com. Thanks for listening! We hope you have a safe and enjoyable holiday season. If you enjoy Thoughts on the Market, please be sure to rate and review us on the Apple Podcast app. It helps more people find the show.

covid-19 new york europe uk market south africa apple podcast delta denmark omicron icu morgan stanley preliminary matthew harrison moderna ceo stephane bancel

Special Episode: Early Vaccine Data on Omicron